Cargando…
Exosomal CD63 in critically ill patients with sepsis
CD63 is one of the tetraspanin protein family members that is ubiquitously expressed on exosomes and is involved in the signal transduction of various types of immune cells. It may thus contribute to immunometabolic mechanisms of cellular and organ dysfunction in sepsis. Nonetheless, the association...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514522/ https://www.ncbi.nlm.nih.gov/pubmed/34645935 http://dx.doi.org/10.1038/s41598-021-99777-w |
_version_ | 1784583409519034368 |
---|---|
author | Im, Yunjoo Yoo, Hongseok Ko, Ryoung-Eun Lee, Jin Young Park, Junseon Jeon, Kyeongman |
author_facet | Im, Yunjoo Yoo, Hongseok Ko, Ryoung-Eun Lee, Jin Young Park, Junseon Jeon, Kyeongman |
author_sort | Im, Yunjoo |
collection | PubMed |
description | CD63 is one of the tetraspanin protein family members that is ubiquitously expressed on exosomes and is involved in the signal transduction of various types of immune cells. It may thus contribute to immunometabolic mechanisms of cellular and organ dysfunction in sepsis. Nonetheless, the association of exosomal CD63 with the severity and mortality of sepsis is not well known. Therefore, in the present study, the overall levels of exosomal CD63 were evaluated to ascertain whether they were associated with organ failure and mortality in patients with sepsis. Exosomal CD63 was measured from prospectively enrolled critically-ill patients with sepsis (n = 217) and healthy control (n = 20). To detect and quantify exosomes in plasma, a commercially available enzyme-linked immunosorbent assay kit was used according to the manufacturer’s protocol. The total number of exosomal CD63 was determined by quantifying the immunoreactive CD63. The association between plasma levels of exosomal CD63 and sequential organ failure assessment (SOFA) score was assessed by a linear regression method. The best cut-off level of exosomal CD63 for 28-day mortality prediction was determined by Youden’s index. Among 217 patients with sepsis, 143 (66%) patients were diagnosed with septic shock. Trends of increased exosomal CD63 levels were observed in control, sepsis, and septic-shock groups (6.6 µg/mL vs. 42 µg/mL vs. 90 µg/mL, p < 0.001). A positive correlation between exosomal CD63 and SOFA scores was observed in patients with sepsis (r value = 0.35). When patients were divided into two groups according to the best cut-off level, the group with higher exosomal CD63 levels (more than 126 µg/mL) was significantly associated with 28-day and in-hospital mortality. Moreover, the Kaplan–Meier survival method showed a significant difference in 90-day survival between patients with high- and low-exosomal CD63 levels (log-rank p = 0.005). Elevated levels of exosomal CD63 were associated with the severity of organ failure and predictive of mortality in critically ill patients with sepsis. |
format | Online Article Text |
id | pubmed-8514522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85145222021-10-14 Exosomal CD63 in critically ill patients with sepsis Im, Yunjoo Yoo, Hongseok Ko, Ryoung-Eun Lee, Jin Young Park, Junseon Jeon, Kyeongman Sci Rep Article CD63 is one of the tetraspanin protein family members that is ubiquitously expressed on exosomes and is involved in the signal transduction of various types of immune cells. It may thus contribute to immunometabolic mechanisms of cellular and organ dysfunction in sepsis. Nonetheless, the association of exosomal CD63 with the severity and mortality of sepsis is not well known. Therefore, in the present study, the overall levels of exosomal CD63 were evaluated to ascertain whether they were associated with organ failure and mortality in patients with sepsis. Exosomal CD63 was measured from prospectively enrolled critically-ill patients with sepsis (n = 217) and healthy control (n = 20). To detect and quantify exosomes in plasma, a commercially available enzyme-linked immunosorbent assay kit was used according to the manufacturer’s protocol. The total number of exosomal CD63 was determined by quantifying the immunoreactive CD63. The association between plasma levels of exosomal CD63 and sequential organ failure assessment (SOFA) score was assessed by a linear regression method. The best cut-off level of exosomal CD63 for 28-day mortality prediction was determined by Youden’s index. Among 217 patients with sepsis, 143 (66%) patients were diagnosed with septic shock. Trends of increased exosomal CD63 levels were observed in control, sepsis, and septic-shock groups (6.6 µg/mL vs. 42 µg/mL vs. 90 µg/mL, p < 0.001). A positive correlation between exosomal CD63 and SOFA scores was observed in patients with sepsis (r value = 0.35). When patients were divided into two groups according to the best cut-off level, the group with higher exosomal CD63 levels (more than 126 µg/mL) was significantly associated with 28-day and in-hospital mortality. Moreover, the Kaplan–Meier survival method showed a significant difference in 90-day survival between patients with high- and low-exosomal CD63 levels (log-rank p = 0.005). Elevated levels of exosomal CD63 were associated with the severity of organ failure and predictive of mortality in critically ill patients with sepsis. Nature Publishing Group UK 2021-10-13 /pmc/articles/PMC8514522/ /pubmed/34645935 http://dx.doi.org/10.1038/s41598-021-99777-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Im, Yunjoo Yoo, Hongseok Ko, Ryoung-Eun Lee, Jin Young Park, Junseon Jeon, Kyeongman Exosomal CD63 in critically ill patients with sepsis |
title | Exosomal CD63 in critically ill patients with sepsis |
title_full | Exosomal CD63 in critically ill patients with sepsis |
title_fullStr | Exosomal CD63 in critically ill patients with sepsis |
title_full_unstemmed | Exosomal CD63 in critically ill patients with sepsis |
title_short | Exosomal CD63 in critically ill patients with sepsis |
title_sort | exosomal cd63 in critically ill patients with sepsis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514522/ https://www.ncbi.nlm.nih.gov/pubmed/34645935 http://dx.doi.org/10.1038/s41598-021-99777-w |
work_keys_str_mv | AT imyunjoo exosomalcd63incriticallyillpatientswithsepsis AT yoohongseok exosomalcd63incriticallyillpatientswithsepsis AT koryoungeun exosomalcd63incriticallyillpatientswithsepsis AT leejinyoung exosomalcd63incriticallyillpatientswithsepsis AT parkjunseon exosomalcd63incriticallyillpatientswithsepsis AT jeonkyeongman exosomalcd63incriticallyillpatientswithsepsis |